Lead Sponsor

Eli Lilly and Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of metastatic Stage IV NSCLC
•At least 1 measurable extra-central nervous system (CNS) lesion
•Documented radiographic progression while on continuous treatment with erlotinib monotherapy
•Objective clinical benefit from erlotinib treatment as defined by either documented partial or complete response or stable disease ≥6 months or, if most recent erlotinib treatment has been initiated based on documented epidermal growth factor receptor mutation (EGFRmt) status, at least 12 weeks stable disease
•Determined to be MET diagnostic positive (+)
•Availability of a tumor sample post-erlotinib progression
•Eastern Cooperative Oncology Group (ECOG) performance status ≤2
•Have adequate organ function

•Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device
•Have previously been treated with LY2875358 or any other MET-targeting experimental therapeutic
•Have a serious concomitant systemic disorder or significant cardiac disease
•Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural effusion, pericardial fluids or ascites, requiring drainage every other week or more frequently
•Have a history of another malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to the study
•Have major surgery less than 2 weeks prior initiation of study treatment therapy
•Pregnant or lactating women
•Have symptomatic CNS metastasis

Related studies

NCT06855771 · Carcinoma, Non-Small-Cell Lung

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

NCT06120140 · Carcinoma, Non-Small-Cell Lung

NCT04165798 · Carcinoma, Non-Small-Cell Lung

NCT06667908 · Carcinoma, Non-Small-Cell Lung

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants